|
Synonyms: GSK-3228836 | GSK-3228836B | GSK-3389404 | GSK3389404 | Hibsago® | IONIS HBVRX | ISIS-505358 | ISIS-GSK3RX
bepirovirsen is an approved drug
Compound class:
Nucleic acid
Comment: Bepirovirsen (GSK3389404) is an antisense oligonucleotide (ASO) therapy that is proposed as a functional cure for chronic hepatitis B, by binding to hepatitis B virus RNA and preventing viral protein translation and replication. It may also mediate HBV mRNA degradation, potentially via the innate immune response initiated by its CpG motif [2]. The molecule is N-acetylgalactosamine (GalNAc)-conjugated to enhance hepatocyte delivery.
Full necletide sequence is all-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine |
| No information available. |
Summary of Clinical Use ![]() |
| Bepirovirsen was progressed as a clinical candidate anti-hepatitis B therapeutic [1]. First approval for clinical use was granted by Japan's PMDA in August 2026. US FDA approval followed in October 2026. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04449029 | A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB) | Phase 2 Interventional | GlaxoSmithKline | 4 | |
| NCT05630820 | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) | Phase 3 Interventional | GlaxoSmithKline | 1 | |
| NCT05630807 | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) | Phase 3 Interventional | GlaxoSmithKline | 1 | |
| NCT03020745 | A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects | Phase 2 Interventional | GlaxoSmithKline | 3 | |